久久精品国产再热青青青,免费无码一区二区三区a片视频,亚洲成a∧人片在线播放调教,欧美成人三级网站现在观看

<menu id="qqo8i"><acronym id="qqo8i"></acronym></menu>

中文 | EN

中文 EN

Expanded Access Policy Press Releases

Home > MEDIA

MEDIA

Expanded Access Policy

17 2021-12

Milestone of SIMR —— The first Phase II clinical study for S

On 17th Dec 2021, Shanghai SIMR Biotechnology Co., Ltd. (here in after referred to as "SIMR" or "Company”) announced that company’s investigational drug SR419, the first asset of SIMR e...
01 2021-11

Milestone - SR1375'S Phase II Clinical Trial Approved by the

Shanghai, China, Nov 1,2021 ---- Shanghai SIMR Biotechnology Co., Ltd. (here in after referred to as "SIMR" or "Company") initiated the first-in-human study of candidate drug SR750...
11 2021-10

Milestone|| Dosing of the first cohort successfully complete

Shanghai, China, October 11, 2021 ---- Shanghai SIMR Biotechnology Co., Ltd. (here in after referred to as "SIMR" o...
20 2020-09

The first patient successfully dosed with the candidate drug

Shanghai, China, September 18, 2020. Shanghai SIMR Biotechnology Co., Ltd. (hereinafter referred to as "SIMR" or &q...
02 2020-09

SIMR completed the first-in-human study of candidate drug SR

Shanghai, China, June 12, 2020 ---- Shanghai SIMR Biotechnology Co., Ltd. (hereinafter referred to as "SIMR" or &qu...
10 2019-09

PharmaBoardroom interviews: Li Shuai – CEO, SIMR, China

Article Source：PharmaBoardroom?Dr Li, could you share the story of how you decided to establish SIMR in 2014?I studied and worked in the Chinese Academy of Sciences (CAS) for 12 years, and during...

Home Previous 1 2 3 4 Next Last

Previous Next Road 4 page 23 strip

<sup id="muyek"></sup>

<blockquote id="muyek"><ul id="muyek"></ul></blockquote>

<li id="muyek"></li>